Close Menu

Back to Basics?

Analyst Tim Anderson says that Pfizer could cut back to become strictly a drug discovery firm. To do so, the company would have to strip itself of "divisions accounting for $32 billion of its $67 billion in sales," adds Matthew Herper at Forbes. Anderson says these "extremely bold" moves would be greeted warmly by investors, though Pfizer has not made any commitments one way or the other.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.